Industry News

FDA Approves Ibrutinib for Pediatric Patients with Chronic Graft-Versus-Host Disease

On August 24, 2022, the U.S  Food and Drug Administration (FDA) approved ibrutinib for the treatment of pediatric patients one year and older with chronic graft-versus-host disease after failure of one or more lines of systemic therapy. 

For more information, read the FDA announcement

Posted 8/25/2022

1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
Email Us